Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

@inproceedings{Platzbecker2012AzacitidineFT,
  title={Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial},
  author={Uwe- Platzbecker and Martin Wermke and Joergen Radke and Uta Oelschlaegel and F Seltmann and Alexander Kiani and I. Klut and Hans Knoth and Christoph R{\"o}llig and Johannes Schetelig and B. Mohr and Xina Graehlert and Gerhard Ehninger and Martin Bornhaeuser and Christian Thiede},
  booktitle={Leukemia},
  year={2012}
}
This study evaluated azacitidine as treatment of minimal residual disease (MRD) determined by a sensitive donor chimerism analysis of CD34+ blood cells to pre-empt relapse in patients with CD34+ myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (HSCT). At a median of 169 days after HSCT, 20/59 prospectively screened patients experienced a decrease of CD34+ donor chimerism to <80% and received four azacitidine cycles (75 mg… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 95 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 42 references

Similar Papers

Loading similar papers…